Skip to main content
Top
Published in: Endocrine 3/2018

01-09-2018 | Original Article

Associations of serum glucagon levels with glycemic variability in type 1 diabetes with different disease durations

Authors: Ke Li, Wen-jing Song, Xia Wu, Dan-yang Gu, Pu Zang, Ping Gu, Bin Lu, Jia-qing Shao

Published in: Endocrine | Issue 3/2018

Login to get access

Abstract

Purpose

Glucagon has been recognized as a pivotal factor implicated in the pathophysiology ofdiabetes. The purpose of this study is to investigate the dynamic secretion levels of serum glucagon (GLA) in patients with type 1 diabetes mellitus (T1DM) with different courses of disease, and to analyze its correlation with blood glucose fluctuation.

Methods

This observational study included 55 T1DM patients and divided into 3 groups according to the courses of disease. Group 1(the disease duration <1 year), Group 2(1≤the disease durations≤5), 3(the disease durations >5 years). All patients underwent a 100g standard steamed buns meal test,measuring the levels of serum glucose, glucagon, insulin, C-peptide in different points of time, and 48 of the total patients used continuous glucose monitoring system (CGMS) to monitor blood glucose.

Results

The fasting glucagon level in Group 1 was significantly higher than it in Group 2. Furthermore, the GLA1h, the GLA3h and the AUCGLA0-3h in Group 1 were greatly larger than those in Group 3. Referring to glycemic variability, the LBGI, AUC of hypoglycemia, the percentage of hypoglycemia time andthe times of nocturnal hypoglycemia in Group 1 were significantly lower than those in Group 3. Moreover,the fasting glucagon level was the independent factors to SD and MAGE. The AUCGLA0-3h were negatively correlated with MODD, LBGI, GRADE-hypo and AUC of nocturnal hypoglycemia.

Conclusions

It is concluded that glucagon secretory function impairs with duration of type 1 diabetes extended and correlates to glycemic fluctuation, especially hypoglycemia.
Literature
1.
go back to reference R.J. Brown, N. Sinaii, K.I. Rother, Too much glucagon, too little insulin: Time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care 31, 1403–1404 (2008)CrossRefPubMedPubMedCentral R.J. Brown, N. Sinaii, K.I. Rother, Too much glucagon, too little insulin: Time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care 31, 1403–1404 (2008)CrossRefPubMedPubMedCentral
2.
go back to reference S. Fredheim, M.M. Andersen, S. Pörksen, L.B. Nielsen, C. Pipper, L. Hansen, J.J. Holst, J. Thomsen, J. Johannesen, H.B. Mortensen, J. Svensson, The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes. Diabetologia 58, 828–834 (2015)CrossRefPubMed S. Fredheim, M.M. Andersen, S. Pörksen, L.B. Nielsen, C. Pipper, L. Hansen, J.J. Holst, J. Thomsen, J. Johannesen, H.B. Mortensen, J. Svensson, The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes. Diabetologia 58, 828–834 (2015)CrossRefPubMed
3.
go back to reference K. Pechhold, X. Zhu, V.S. Harrison, J. Lee, S. Chakrabarty, K. Koczwara, O. Gavrilova, D.M. Harlan, Dynamic changes in pancreatic endocrine cell abundance, distribution, and function in antigen-induced and spontaneous autoimmune diabetes. Diabetes 58, 1175–1184 (2009)CrossRefPubMedPubMedCentral K. Pechhold, X. Zhu, V.S. Harrison, J. Lee, S. Chakrabarty, K. Koczwara, O. Gavrilova, D.M. Harlan, Dynamic changes in pancreatic endocrine cell abundance, distribution, and function in antigen-induced and spontaneous autoimmune diabetes. Diabetes 58, 1175–1184 (2009)CrossRefPubMedPubMedCentral
4.
go back to reference M. Waguri, T. Hanafusa, N. Itoh, J. Miyagawa, A. Imagawa, M. Kuwajima, N. Kono, Y. Matsuzawa, Histopathologic study of the pancreas shows a characteristic lymphocytic infiltration in Japanese patients with IDDM. Endocr. J. 44, 23–33 (1997)CrossRefPubMed M. Waguri, T. Hanafusa, N. Itoh, J. Miyagawa, A. Imagawa, M. Kuwajima, N. Kono, Y. Matsuzawa, Histopathologic study of the pancreas shows a characteristic lymphocytic infiltration in Japanese patients with IDDM. Endocr. J. 44, 23–33 (1997)CrossRefPubMed
5.
go back to reference The Diabetes Control and Complications Trial Research Group. to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44, 968–983 (1995). The Diabetes Control and Complications Trial Research Group. to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44, 968–983 (1995).
6.
go back to reference H.Y. Jin, K.A. Lee, T.S. Park, The impact of glycemic variability on diabetic peripheral neuropathy. Endocrine 53, 643–648 (2016)CrossRefPubMed H.Y. Jin, K.A. Lee, T.S. Park, The impact of glycemic variability on diabetic peripheral neuropathy. Endocrine 53, 643–648 (2016)CrossRefPubMed
7.
go back to reference A.J. Graveling, B.M. Frier, The risks of nocturnal hypoglycaemia in insulin-treated diabetes. Diabetes Res. Clin. Pract. 133, 30–39 (2017)CrossRefPubMed A.J. Graveling, B.M. Frier, The risks of nocturnal hypoglycaemia in insulin-treated diabetes. Diabetes Res. Clin. Pract. 133, 30–39 (2017)CrossRefPubMed
8.
go back to reference S. Pörksen, L.B. Nielsen, A. Kaas, M. Kocova, F. Chiarelli, C. Ørskov, J.J. Holst, K.B. Ploug, P. Hougaard, L. Hansen, H.B. Mortensen, Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes. J. Clin. Endocrinol. Metab. 92, 2910–2916 (2007)CrossRefPubMed S. Pörksen, L.B. Nielsen, A. Kaas, M. Kocova, F. Chiarelli, C. Ørskov, J.J. Holst, K.B. Ploug, P. Hougaard, L. Hansen, H.B. Mortensen, Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes. J. Clin. Endocrinol. Metab. 92, 2910–2916 (2007)CrossRefPubMed
9.
go back to reference T. Urakami, N. Nagano, J. Suzuki, A. Yoshida, S. Takahashi, H. Mugishima, Influence of plasma glucagon levels on glycemic control in children with type 1 diabetes. Pediatr. Int. 53, 46–49 (2011)CrossRefPubMed T. Urakami, N. Nagano, J. Suzuki, A. Yoshida, S. Takahashi, H. Mugishima, Influence of plasma glucagon levels on glycemic control in children with type 1 diabetes. Pediatr. Int. 53, 46–49 (2011)CrossRefPubMed
10.
go back to reference A. Plesner, H.J. Ten, C.B. Verchere, Islet remodeling in female mice with spontaneous autoimmune and streptozotocin-induced diabetes. PLoS ONE 9, e102843 (2014)CrossRefPubMedPubMedCentral A. Plesner, H.J. Ten, C.B. Verchere, Islet remodeling in female mice with spontaneous autoimmune and streptozotocin-induced diabetes. PLoS ONE 9, e102843 (2014)CrossRefPubMedPubMedCentral
11.
go back to reference A. Willcox, S.J. Richardson, A.J. Bone, A.K. Foulis, N.G. Morgan, Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes. Diabetologia 53, 2020–2028 (2010)CrossRefPubMed A. Willcox, S.J. Richardson, A.J. Bone, A.K. Foulis, N.G. Morgan, Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes. Diabetologia 53, 2020–2028 (2010)CrossRefPubMed
12.
go back to reference I.B. Hirsch, M. Brownlee, Should minimal blood glucose variability become the gold standard of glycemic control? J. Diabetes Complicat. 19, 178–181 (2005)CrossRefPubMed I.B. Hirsch, M. Brownlee, Should minimal blood glucose variability become the gold standard of glycemic control? J. Diabetes Complicat. 19, 178–181 (2005)CrossRefPubMed
13.
go back to reference D. Cox, L. Gonder-Frederick, A. McCall, B. Kovatchev, W. Clarke, The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and hyperglycaemia among adults with type 1 or type 2 diabetes. Int. J. Clin. Pract Suppl. 129, 20–26 (2002). D. Cox, L. Gonder-Frederick, A. McCall, B. Kovatchev, W. Clarke, The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and hyperglycaemia among adults with type 1 or type 2 diabetes. Int. J. Clin. Pract Suppl. 129, 20–26 (2002).
14.
go back to reference N. Mauras, L. Fox, K. Englert, R.W. Beck, Continuous glucose monitoring in type 1 diabetes. Endocrine 43, 41–50 (2013)CrossRefPubMed N. Mauras, L. Fox, K. Englert, R.W. Beck, Continuous glucose monitoring in type 1 diabetes. Endocrine 43, 41–50 (2013)CrossRefPubMed
15.
go back to reference M. Egi, R. Bellomo, E. Stachowski, C.J. French, G. Hart, Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 105, 244–252 (2006)CrossRefPubMed M. Egi, R. Bellomo, E. Stachowski, C.J. French, G. Hart, Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 105, 244–252 (2006)CrossRefPubMed
16.
go back to reference L. Monnier, C. Colette, D.R. Owens, Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes Metab. Res. Rev. 25, 393–402 (2009)CrossRefPubMed L. Monnier, C. Colette, D.R. Owens, Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes Metab. Res. Rev. 25, 393–402 (2009)CrossRefPubMed
17.
go back to reference C.M. McDonnell, S.M. Donath, S.I. Vidmar, G.A. Werther, F.J. Cameron, A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol. Ther. 7, 253–263 (2005)CrossRefPubMed C.M. McDonnell, S.M. Donath, S.I. Vidmar, G.A. Werther, F.J. Cameron, A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol. Ther. 7, 253–263 (2005)CrossRefPubMed
18.
go back to reference B.P. Kovatchev, D.J. Cox, A. Kumar, L. Gonder-Frederick, W.L. Clarke, Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol. Ther. 5, 817–828 (2003)CrossRefPubMed B.P. Kovatchev, D.J. Cox, A. Kumar, L. Gonder-Frederick, W.L. Clarke, Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol. Ther. 5, 817–828 (2003)CrossRefPubMed
19.
go back to reference D.J. Cox, L. Gonder-Frederick, L. Ritterband, W. Clarke, B.P. Kovatchev, Prediction of Severe Hypoglycemia. Diabetes Care 30, 1370–1373 (2007)CrossRefPubMed D.J. Cox, L. Gonder-Frederick, L. Ritterband, W. Clarke, B.P. Kovatchev, Prediction of Severe Hypoglycemia. Diabetes Care 30, 1370–1373 (2007)CrossRefPubMed
20.
go back to reference A.H. El-Laboudi, I.F. Godsland, D.G. Johnston, N.S. Oliver, Measures of glycemic variability in type 1 diabetes and the effect of real-time continuous glucose monitoring. Diabetes Technol. Ther. 18, 806–812 (2016)CrossRefPubMed A.H. El-Laboudi, I.F. Godsland, D.G. Johnston, N.S. Oliver, Measures of glycemic variability in type 1 diabetes and the effect of real-time continuous glucose monitoring. Diabetes Technol. Ther. 18, 806–812 (2016)CrossRefPubMed
21.
go back to reference N.R. Hill, N.S. Oliver, P. Choudhary, J.C. Levy, P. Hindmarsh, D.R. Matthews, Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol. Ther. 13, 921–928 (2011)CrossRefPubMedPubMedCentral N.R. Hill, N.S. Oliver, P. Choudhary, J.C. Levy, P. Hindmarsh, D.R. Matthews, Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol. Ther. 13, 921–928 (2011)CrossRefPubMedPubMedCentral
Metadata
Title
Associations of serum glucagon levels with glycemic variability in type 1 diabetes with different disease durations
Authors
Ke Li
Wen-jing Song
Xia Wu
Dan-yang Gu
Pu Zang
Ping Gu
Bin Lu
Jia-qing Shao
Publication date
01-09-2018
Publisher
Springer US
Published in
Endocrine / Issue 3/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1641-1

Other articles of this Issue 3/2018

Endocrine 3/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.